JAMONY
TSRX

Jacob Asset Management of New York’s TRIUS THERAPEUTICS INC COM STK (DE) TSRX Stock Holding History

Jacob Asset Management of New York’s Portfolio TSRX Stock Details TSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-56,300
Closed -$457K – 115
2013
Q2 		$457K Buy
+56,300
New +$416K 0.62% 48

Other funds holding TSRX

PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Jacob Asset Management of New York's TSRX Position: Q3 2013 in Review

Jacob Asset Management of New York sold out of TRIUS THERAPEUTICS INC COM STK (DE) (TSRX) in Q3 2013, closing a stake of 56,300 shares — an estimated $457K sold.

Jacob Asset Management of New York first reported a position in TSRX in Q2 2013 and held it in 1 quarter. The position peaked at $457K in Q2 2013. 7 funds tracked by Wall St. Rank hold TSRX as of Q3 2013.

  • Jacob Asset Management of New York reported no remaining TRIUS THERAPEUTICS INC COM STK (DE) position as of Q3 2013 after selling out during the quarter.
  • Jacob Asset Management of New York sold 56,300 TRIUS THERAPEUTICS INC COM STK (DE) shares in Q3 2013, an estimated $457K.
  • Jacob Asset Management of New York first reported a position in TRIUS THERAPEUTICS INC COM STK (DE) in Q2 2013 and held it in 1 quarter.
  • Jacob Asset Management of New York's TRIUS THERAPEUTICS INC COM STK (DE) position peaked at $457K in Q2 2013.
  • 7 funds tracked by Wall St. Rank held TRIUS THERAPEUTICS INC COM STK (DE) as of Q3 2013.

Based on Jacob Asset Management of New York's 13F filing for Q3 2013, filed 14 Nov 2013.